Question 1

What is AviadoBio?

Accepted Answer

AviadoBio is a Entity.

Question 2

How often does AviadoBio appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was AviadoBio first tracked by Ergen?

Accepted Answer

First tracked on Jun 16, 2026.

Question 4

When was AviadoBio last mentioned in news?

Accepted Answer

Last active on Jun 17, 2026.

Question 5

What is AviadoBio's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is AviadoBio in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving AviadoBio?

Accepted Answer

AviadoBio expands vMiX license with King's College London (Jun 16, 2026, 6 articles).

Question 8

How did the "AviadoBio expands vMiX license with King's College London" event impact AviadoBio?

Accepted Answer

AviadoBio expanded its exclusive license agreement with King s College London for the vMiX RNAi gene silencing platform, allowing it to apply the technology across all human therapeutic areas. This positions AviadoBio to maximize the value of vMiX and pursue strategic partnerships beyond its core neuroscience pipeline.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.